A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

Status:
RECRUITING

Trial end date:
2029-08-31

Target enrollment:

Participant gender:

To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.

PHASE2

M.D. Anderson Cancer Center

Rigel Pharmaceuticals

olutasidenib